

An Overview of Childhood Vaccination, Benefits and Complications

¹Hussain Nasser Kariri, ²Ayman Mohammad Aboalam,
³Hassan saeed al azlal alshahrani, ⁴Amjad turki Ahmed fakieh,
⁵Saad Husain Saad Shabeeb, ⁶Bader ali asiri, ⁷Saeed Mubarak Mohammed Alahmari,
⁸Yahya Hadi Mohammed Zakri

Abstract: Childhood vaccination continues to be the most efficient public health method to prevent and control contagious diseases. Vaccination has been described as among the greatest public health accomplishments of the 20th century. This review was aimed to overview the childhood vaccination from different perspectives, and to discuss the complications (adverse effects) and benefits these vaccinations on children health and on this life. was developed an electronic search in MEDLINE, & Embase, PsychInfo, Cochrane, CINAHL databases, through the time up to December 2016, our search strategy used several terms including; vaccine, immunis, immunize AND combined with; attitude, side effects, benefits, complications distrust mistrust, awareness dropout, misinformation barrier, belief, fear, Rejection opposition choice. Articles search was limited to English published, and Human subject related articles, we included only those trails which discussing vaccination for infants and children aged under 12 years old. The majority of the infections targeted by youth vaccines have the possible to cause neurologic problems and subsequent special needs. Taken together, the burden for moms and dads and society in taking care of affected kids is substantial. Of higher importance is our finding that kids are at risk of having lower vaccination coverage if their moms and dads have a bad working relationship with their child's vaccination service provider or mistrust the medical profession in general.

Keywords: Childhood vaccination, MEDLINE, & Embase, PsychInfo, Cochrane, CINAHL databases.

1. INTRODUCTION

Childhood vaccination continues to be the most efficient public health method to prevent and control contagious diseases ⁽¹⁾. Vaccination has been described as among the greatest public health accomplishments of the 20th century ⁽¹⁾, and is widely viewed as affordable and beneficial public health procedure. Almost 22 million infants, mainly in low- and middle-income nations, did not get the complete series of fundamental immunisations in 2012 ^(2,3,4), contributing to 1.5 million preventable deaths (5). A variety of research studies and reviews have actually explored the factors for vaccine hesitancy and the non-vaccination of kids ^(6,7,8). In general, they highlight that vaccination decision making is a complicated procedure, affected by lots of factors. An important barrier for people in lots of settings is an absence of suitable info, resulting in doubts about the trade-offs between the advantages and damages of vaccination and to worries about adverse effects or other implications ^(9,10,11,12). Individuals might do not have understanding about how vaccinations 'work' and about the diseases that vaccines avoid ^(9,11,13). When interaction about vaccination is poor or insufficient it can adversely impact vaccination rates and undermine vaccine approval ⁽⁶⁾. For that reason, improving interaction about vaccination is a key factor in enhancing vaccination outcomes ^(14,15) and achieving the wider objective of knowledgeable moms and dads and communities-- essential contributors to enhancing child health in lots of settings ^(16,17,18).

The National Advisory Committee on Immunization (NACI) provides the federal government (i.e. Canadian Healthcare) with prompt and ongoing medical, clinical and public health guidance connecting to immunization ⁽¹⁹⁾. The existing NACI-recommended immunization schedule for kids is summarized in (Figure 1) ⁽¹⁹⁾.

Age at Vaccination	DTaP	IPV	Hib	MMR	dTap λ or Td	HepB (3 doses)	V λ	PC λ	MC λ	Influenza
Birth						Infancy or pre-adolescence				Before influenza season in those over 6 months, esp. in high risk categories
2 months	x	x	x					x	x	
4 months	x	x	x					x	x	
6 months	x	x	x					x	x	
12 months				X			x	x	x	
18 months	x	x	x	x or						
4–6 years				X						
14–16 years					x				x	

DTaP Diphtheria, tetanus, pertussis (acellular), infant and young-child-type vaccine

IPV Inactivated polio vaccine

Hib *Haemophilus influenzae* type-b conjugate vaccine

MMR Measles, mumps, rubella vaccine

dTap Tetanus and diphtheria toxoid, (acellular) pertussis, adolescent/adult-type vaccine

Td Tetanus and diphtheria toxoid, adult-type vaccine

HepB Hepatitis B vaccine

V Varicella vaccine

PC Pneumococcal conjugate vaccine

MC Meningococcal conjugate vaccine

Influenza Influenza virus vaccine

* Conjugated pneumococcal vaccine: Doses at 2, 4 and 6 months, followed by one dose at 12–15 months of age.⁸

** Conjugated meningococcal vaccine: If started at 2 months — 3 doses; if started at 4 to 11 months — 2 doses; if started at \geq 12 months — 1 dose.⁹

λ While all recommended by NACI, acellular pertussis for adolescents, varicella, conjugated pneumococcal, and conjugated meningococcal vaccines are not currently available in all Canadian provincial and territorial infant and childhood immunization programs.

Figure1: NACI-recommended Immunization Schedule for Infants and Children (Ref# 19)

This review was aimed to overview the childhood vaccination from different perspectives, and to discuss the complications (adverse effects) and benefits these vaccinations on children health and on this life.

2. METHODS

Search strategy:

was developed an electronic search in MEDLINE, & Embase, PsychInfo, Cochrane, CINAHL databases, through the time up to December 2016, our search strategy used several terms including; vaccine, immunis, immunize AND combined with; attitude, side effects, benefits, complications distrust mistrust, awareness dropout, misinformation barrier, belief, fear, Rejection opposition choice. Articles search was limited to English published, and Human subject related articles, we included only those trails which discussing vaccination for infants and children aged under 12 years old.

3. RESULTS & DISCUSSION

The high rate of youth vaccination protection in the majority of industrialized countries indicates that vaccination stays an extensively accepted public health measure ⁽²⁰⁾. These national price quotes may conceal clusters of under-vaccinated individuals ⁽²¹⁾. Current break outs of vaccine-preventable diseases (VPD), including measles ^(22,23), poliomyelitis, ⁽²⁴⁾ and pertussis ⁽²⁵⁾ in numerous parts of the industrialized world have been connected mainly to non-vaccinated or under-vaccinated communities ⁽²⁶⁾. In addition, outcomes of numerous studies have actually shown that even vaccinated individuals can have essential doubts and issues concerning vaccination ^(27,28,29,30). Indeed, numerous professionals think about that vaccination programs are threatened by growing issues amongst the population concerning the security and effectiveness of vaccines ^(31,32,33,34). It is approximated that less than 5-10% of people have strong anti-vaccination convictions ⁽³⁵⁾. Nevertheless, a more significant proportion could be classified as being reluctant concerning vaccination ⁽³⁵⁾.

Benefits of Routine Vaccination for children:

Not many years ago parents and health care employees alike saw first-hand the possible effects for infants and kids who became infected with the diseases now avoided by routine immunization programs. In the early 1900s, 5 from every 1,000 kids born in Canada and the United States died from pertussis (whooping cough) before they reached their 5th birthday ⁽³⁶⁾ and diphtheria (bacteria triggering disease that impedes swallowing and breathing) was one of the most typical causes of death in children from 1 to 5 years of age, eliminating thousands of children each year ⁽¹⁹⁾. Polio (an infectious viral disease affecting the central nervous system) was a much feared summer scourge that frequently eliminated or paralyzed ⁽³⁷⁾.

To reap the benefit from these vaccines, kids should be immunized and vaccinated on time. These diseases can still kill or incapacitate, even when there is access to modern day extensive care and antibiotic treatment ^(38,39,40). In the mid 1990s, numerous households living in the Russian Federation were retaught the lesson of the risks of diphtheria and the significance of immunization as diphtheria made a significant renewal with more than 115,000 cases and 3,000 deaths reported ⁽³⁹⁾. This outbreak occurred in a country where diphtheria had formerly been well controlled. The breakup of the previous USSR led to extensive social changes that included a significant fall off in immunization rates for infants and kids and a failure to offer booster doses to adults. Case control research studies revealed that those who were inoculated were secured; those who were not remained in problem ⁽⁴¹⁾. This terrible epidemic was due not to vaccine failure, but to a failure to immunize.

Complications (side effects of Vaccines):

(Table 1) presents the impacts of the disease and the recognized adverse effects of the vaccine for the regular vaccine-preventable diseases for infants and children ^(19,42,43). In general, all of these diseases are major and might be deadly, while the vaccine adverse occasions, if they happen, are usually small such as local discomfort and/or inflammation at the site of the injection and/or mild fever or rash. Research study has actually revealed that the local pain of intramuscular infant immunization with DTaP/IPV/Hib can be decreased by the use of topical lidocaine-prilocaine without adversely affecting the advancement of the protective action from the multicomponent vaccine ⁽⁴⁴⁾ and the pain of numerous infant injections given throughout the exact same check out can be decreased by oral sucrose, oral tactile stimulation (a bottle or pacifier) and parental holding ⁽⁴⁵⁾.

Table 1: Comparison of Effects of Serious Infant and Childhood Diseases and Adverse Effects of Vaccines (Ref# 19,42,43)

Disease / Organism	Effects of Disease	Side Effects of Vaccines
Polio	4–8% have minor illness, 1% get severe disease- paralytic polio, 1 in 20 hospitalized patients die and 50% remain paralyzed.	Local discomfort or redness at the site of injection in 5%. Killed vaccine so no risk of vaccine-associated polio.
Diphtheria	5–10% of cases die even with ICU care, antitoxin and antibiotics. The toxin may lead to neurological and cardiac complications.	DTaP vaccine: Local discomfort, swelling and /or redness at the site of injection in 20%, fever in 5%. A transient nodule may occur at the injection site,

		lasting for a few weeks. Up to 70% develop redness and swelling at the 4-6yr booster.
Tetanus (lock jaw)	10% of cases die, even with ICU care, antitoxin and antibiotics. Risk is greatest for the very young and the very old.	See above for DTaP. Local reactions increase with age, esp. in adults with Td boosters. Peripheral nerve damage has rarely been reported (<1/1,000,000).
Pertussis (whooping cough)	1/400 infants with pertussis die, 1/400 sustain permanent brain damage. If under 6 months, 1% of cases die from pneumonia or fatal oxygen deprivation of the brain.	As above for DTaP. Far fewer side effects with the acellular pertussis (aP) vaccine than the previous whole-cell pertussis vaccine (P).
<i>Haemophilus influenzae</i> type b	5% of cases of meningitis die, 10–15% have permanent brain damage and 10–20% have deafness.	Usually in combination, as with DTaP/IPV/Hib. See above for side effects (same as for DTaP).
Measles	10% have complications such as pneumonia, ear infections. 1/1,000 have encephalitis (infection of the brain) with 10% dying and 25% being left with permanent brain damage, 1/25,000 have SSPE (a delayed fatal degenerative brain disease).	Usually in combination, as with MMR. 5–10% have discomfort or local swelling and fever, with or without a rash. 1/24,000 have low platelets < 1/1,000,000 have encephalitis.
Mumps	1/20 develop aseptic meningitis (viral infection of tissues and fluids around the brain). 1/200 develop encephalitis. 1/200,000 are left deaf. Inflammation of testicles in 20–30% of males; inflammation of ovaries in 5% of post-pubertal females.	Local discomfort, swelling and redness or fever in 5–10%. 1% develop parotitis (swelling of the largest salivary gland, the parotid). 1 in 3 million develop aseptic meningitis.
Rubella	50% have rash, swollen glands, fever; 50% of adolescents and adults have arthritis and arthralgias; 1/6,000 have encephalitis. In the first 10 weeks of pregnancy, 85% risk of congenital rubella syndrome causes death of fetus, deafness, blindness and/or heart disease.	10% have local discomfort and fever, 5% have swollen glands, arthralgias (esp. adults), stiff neck. 1% develop noninfectious rash.
Influenza	Highest mortality rate in those over 65 years and in infants aged <12 months. Complications: pneumonia, febrile seizures, encephalitis, myocarditis, and myositis, Reye's syndrome.	Local mild reactions at injection site and/or low fever for 1 to 2 days in up to 60%. Occasional mild oculorespiratory syndrome. Rare: Guillian-Barre syndrome 1/1,000,000.
Hepatitis B	Variable: asymptomatic to overwhelming liver disease. Neonate asymptomatic, 5–15% of 1 to 5 year olds have symptoms, 33–50% older children egg nausea, jaundice, fever, vomiting, big liver, spleen. < 1% fulminating fatal liver failure. Chronic disease 90% infants, 25–50% of 1 to 5years, and 6 to 10% older children.	15% experience local discomfort and occasionally experience low-grade fever.

	Risk liver cancer, liver failure with chronic disease.	
Varicella (chicken pox)	Death rate 1–3 /100,000 cases in children. Complications in 5–10% of previously healthy children: pneumonia, encephalitis (1/5,000), cerebellar ataxia (1/4,000), osteomyelitis, hepatitis, septic arthritis. In 50% of children who get flesh-eating disease (necrotizing fasciitis), chicken pox precedes it. Shingles in adults. Congenital varicella syndrome.	15–20% experience mild swelling, discomfort at injection site and/or fever. 1–5% develop mild rash.
<i>Streptococcus pneumoniae</i>	Leading cause of invasive bacterial disease in young children. Annual cases: 65 meningitis (hearing loss 20–30%, brain damage 15–20%), 700 cases bacteremia, 2,200 cases hospitalized with pneumonia, 9,000 cases non-hospitalized pneumonia. Case fatality rate <6 months 4.3%, 12 years 2%. 15 deaths/year in <5 years. Sickle cell disease, HIV more at risk bad disease.	Heptavalent infant/ toddler conjugate vaccine well tolerated. Mild local reactions from 10–15%.
<i>Neisseria meningitidis</i>	Meningitis 30–50% (MR 5%), meningitis + bacteremia 40%, bacteremia alone 7–10% (MR 20-40%). Other complications: arthritis, pneumonia, peritonitis. Case fatality rate 10% despite ICU/antibiotics. Highest mortality rate (MR): <1 year 1/100,000	Infant/toddler conjugate C vaccine: local mild reactions less common than with DTaP/IPV/Hib, severe reactions are very rare.

4. CONCLUSION

The majority of the infections targeted by youth vaccines have the possible to cause neurologic problems and subsequent special needs. Taken together, the burden for moms and dads and society in taking care of affected kids is substantial. Of higher importance is our finding that kids are at risk of having lower vaccination coverage if their moms and dads have a bad working relationship with their child's vaccination service provider or mistrust the medical profession in general.

REFERENCES

- [1] Centers for Disease Control Prevention Ten great public health achievements--United States, 1900-1999. MMWR Morbidity Mortality Weekly Repor. 1999;48(12):241.
- [2] WHO UNICEF. Progress Towards Global Immunization Goals - 2012: Summary presentation of key indicators. 2013.
- [3] Bosch Capblanch X, Banerjee K, Burton A. Unvaccinated children in years of increasing coverage: how many and who are they? Evidence from 96 low and middle income countries. Trop Med Int Health. 2012;17(6):697–710. doi: 10.1111/j.1365-3156.2012.02989.x.
- [4] WHO . Progress Towards Global Immunization Goals - 2013: Summary presentation of key indicators. Geneva: WHO; 2014.
- [5] WHO, UNICEF. Global immunization data. 2014.
- [6] WHO. Report of the SAGE Working Group on Vaccine Hesitancy. 2014.
- [7] Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger JA. Vaccine hesitancy: An overview. Human Vaccines & Immunotherapeutics. 2013;9(8):1763–73. doi: 10.4161/hv.24657.

- [8] Larson HJ, Jarrett C, Eckersberger E, Smith D, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012. *Vaccine*. 2014;32(19):2150–9. doi: 10.1016/j.vaccine.2014.01.081.
- [9] Casiday R, Cresswell T, Wilson D, Panter-Brick C. A survey of UK parental attitudes to the MMR vaccine and trust in medical authority. *Vaccine*. 2006;24(2):177–84. doi: 10.1016/j.vaccine.2005.07.063.
- [10] Hadjikoumi I, Niekerk K, Scott C. MMR Catch up Campaign: reasons for refusal to consent. *Arch Dis Child*. 2006;91(7):621. doi: 10.1136/adc.2005.088898.
- [11] Mills E, Jadad AR, Ross C, Wilson K. Systematic review of qualitative studies exploring parental beliefs and attitudes toward childhood vaccination identifies common barriers to vaccination. *J Clin Epidemiol*. 2005;58(11):1081–8. doi: 10.1016/j.jclinepi.2005.09.002.
- [12] Pearce A, Law C, Elliman D, Cole TJ, Bedford H. Factors associated with uptake of measles, mumps, and rubella vaccine (MMR) and use of single antigen vaccines in a contemporary UK cohort: prospective cohort study. *BMJ*. 2008;336(7647):754–7. doi: 10.1136/bmj.39489.590671.25.
- [13] Taylor JA, Darden PM, Brooks DA, Hendricks J, Wasserman RC, Bocian AB. Association between parents' preferences and perceptions of barriers to vaccination and the immunization status of their children: a study from Pediatric Research in Office Settings and the National Medical Association. *Pediatrics*. 2002;110(6):1110–6. doi: 10.1542/peds.110.6.1110.
- [14] Woo EJ, Ball R, Bostrom A, Shadomy SV, Ball LK, Evans G, et al. Vaccine risk perception among reporters of autism after vaccination: vaccine adverse event reporting system 1990–2001. *Am J Public Health*. 2004;94(6):990–5. doi: 10.2105/AJPH.94.6.990.
- [15] Jheeta M, Newell J. Childhood vaccination in Africa and Asia: the effects of parents' knowledge and attitudes. *Bull World Health Organ*. 2008;86(6):419. doi: 10.2471/BLT.07.047159.
- [16] Independent Monitoring Board of the Global Polio Eradication Initiative. 2011.
- [17] Cleland J, Bicego G, Fegan G. Socioeconomic inequalities in childhood mortality: the 1970s to the 1980s. *Health Transit Rev*. 1992;2:1–18.
- [18] Unicef. UNICEF Annual Report 2010. New York, USA: UNICEF; 2011.
- [19] National Advisory Committee on Immunization. *Canadian Immunization Guide*. 6th ed. Ottawa, Ontario: Health Canada; 2002. Available at: <http://dsp-psd.communication.gc.ca/Collection/H49-8-2002E.pdf>.
- [20] World Health Organization. Immunization summary - A statistical reference containing data through 2010. 2012.
- [21] Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. *N Engl J Med*. 2009;360:1981–8.
- [22] Parent du Châtelet I, Antona D, Freymuth F, Muscat M, Halftermeyer-Zhou F, Maine C, et al. Spotlight on measles 2010: update on the ongoing measles outbreak in France, 2008–2010. *Euro Surveill*. 2010;15:15.
- [23] De Serres G, Markowski F, Toth E, Landry M, Auger D, Mercier M, et al. Largest measles epidemic in North America in a decade--Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events. *J Infect Dis*. 2013;207:990–8.
- [24] Oostvogel PM, van Wijngaarden JK, van der Avoort HGAM, Mulders MN, Conyn-van Spaendonck MAE, Rümke HC, et al. Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992–93. *Lancet*. 1994;344:665–70.
- [25] Centers for Disease Control and Prevention (CDC) Notes from the field: Pertussis—California, January–June 2010. *Morbidity and Mortality Weekly Report*. 2010;59:817.
- [26] Falagas ME, Zarkadoulia E. Factors associated with suboptimal compliance to vaccinations in children in developed countries: a systematic review. *Curr Med Res Opin*. 2008;24:1719–41.

- [27] Kennedy A, Lavail K, Nowak G, Basket M, Landry S. Confidence about vaccines in the United States: understanding parents' perceptions. *Health Aff (Millwood)* 2011;30:1151–9.
- [28] Burton-Jeangros C, Golay M, Sudre P. [Compliance and resistance to child vaccination: a study among Swiss mothers] *Rev Epidemiol Sante Publique*. 2005;53:341–50.
- [29] Wu AC, Wisler-Sher DJ, Griswold K, Colson E, Shapiro ED, Holmboe ES, et al. Postpartum mothers' attitudes, knowledge, and trust regarding vaccination. *Matern Child Health J*. 2008;12:766–73.
- [30] Casiday R, Cresswell T, Wilson D, Panter-Brick C. A survey of UK parental attitudes to the MMR vaccine and trust in medical authority. *Vaccine*. 2006;24:177–84.
- [31] Black S, Rappuoli R. A crisis of public confidence in vaccines. *Sci Transl Med*. 2010;2:mr1. doi: 10.1126/scitranslmed.3001738.
- [32] Poland GA, Jacobson RM, Ovsyannikova IG. Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics. *Vaccine*. 2009;27:3240–4. doi: 10.1016/j.vaccine.2009.01.069.
- [33] MacDonald NE, Smith J, Appleton M. Risk perception, risk management and safety assessment: what can governments do to increase public confidence in their vaccine system? *Biologicals*. 2012;40:384–8.
- [34] Leask J, Braunack-Mayer A, Kerridge I. Consent and public engagement in an era of expanded childhood immunisation. *J Paediatr Child Health*. 2011;47:603–7. doi: 10.1111/j.1440-1754.2011.02160.x.
- [35] Leask J. Target the fence-sitters. *Nature*. 2011;473:443–5. doi: 10.1038/473443a.
- [36] Cherry JD, Brunell PA, Golden GS, Karson DT. Report of the task force on pertussis and pertussis immunization. *Pediatrics* 1988;81(suppl):939-984.
- [37] Ruttly CJ. The middle-class plague: epidemic polio and the Canadian state, 1936-1937. *Bulletin Canadien d'Histoire de la Medecine / Canadian Bulletin of Medical History* 1996;13(2):277-314.
- [38] Samba E, Nkrumah F, Leke R. Getting polio eradication back on track in Nigeria. *New England Journal of Medicine* 2004;350(7):645-646.
- [39] Markina SS, Maksimova NM, Vitek CR, Bogatyreva EY, Monisov AA. Diphtheria in the Russian Federation in the 1990s. *Journal of Infectious Diseases* 2000;181(Suppl 1):S27-S34.
- [40] Grewal S, Scheifele D. Haemophilus influenzae type b disease at 11 pediatric centres, 1996-1997. *CCDR - Canada Communicable Disease Report* 1998;24(13):105-108.
- [41] Bisgard KM, Rhodes P, Hardy IRB, Litkina IL, Filatov NN, Monisov AA, Wharton M. Diphtheria toxoid vaccine effectiveness: A case controlled study in Russia. *Journal of Infectious Diseases* 2000;181(Suppl 1):S184-S187.
- [42] National Advisory Committee on Immunization. Statement on recommended use of pneumococcal conjugate vaccine. *CCDR – Canada Communicable Disease Report* 2002;28(ACS-2):1-32.
- [43] National Advisory Committee on Immunization. Statement on recommended use of meningococcal vaccines. *CCDR – Canada Communicable Disease Report* 2001;27(ACS-6):2-36.
- [44] Halperin BA, Halperin SA, McGrath P, Smith B, Houston T. Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. *Pediatric Infectious Disease Journal* 2002;21(5):399-405.
- [45] Reis EC, Roth EK, Syphan JL, Tarbell SE, Holubkov R. Effective pain reduction for multiple immunization injections in young infants. *Archives of Pediatrics and Adolescent Medicine* 2003;157(11):1115-1120.